Prostatype Genomics

Content of the newsletter:

CEO Fredrik Rickman on how the company will use the issue proceeds
- Strong outcome in the issue with support from existing and new large shareholder
- Ongoing activities towards significantly increased sales focus in the US market
- Target to take a significant market share in the US market, while at the same time achieve positive cash flow by the end of 2026

Increased sales resources in the US market starting in Q1 2025
- Business plan for the US market in 2025-2026 is now being finalized
- Inhouse sales force is expected to be recruited and start in Q1 2025 given Medicare approval

Exciting developments in selected EMEA markets
- The number of signed agreements in Spain for the use of the company's gene test is increasing, currently agreements with around 30 public and private healthcare providers
- Patient use in Taiwan leading to sales revenue is expected from the autumn of 2024
- Ongoing discussions on potentially establishing in more EMA markets, for example Italy

Read the full newsletter and subscribe via this link:
https://bit.ly/progensep24en

Prostatype Genomics' newsletter is published to offer broader and more in-depth information about the company's operations and progress. It is produced together with the IR communications agency Honeybadger, https://www.honeybadger.se/en/

For more information, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0)73 049 77 01
Email: fredrik.rickman@prostatypegenomics.com

About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.